Xilio Therapeutics, Inc. (XLO): Price and Financial Metrics
GET POWR RATINGS... FREE!
XLO Stock Price Chart Interactive Chart >
XLO Price/Volume Stats
| Current price | $3.24 | 52-week high | $27.95 |
| Prev. close | $3.06 | 52-week low | $2.30 |
| Day low | $3.04 | Volume | 83,500 |
| Day high | $3.50 | Avg. volume | 38,944 |
| 50-day MA | $5.04 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 89.01M |
Xilio Therapeutics, Inc. (XLO) Company Bio
Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune system for cancer patients. Its checkpoint inhibitor programs include XTX101, is a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1 clinical trials in patients with solid tumors; and cytokine programs comprise XTX202, XTX301, and XTX401, which are modified form of IL-2 that is masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Latest XLO News From Around the Web
Below are the latest news stories about Xilio Therapeutics Inc that investors may wish to consider to help them evaluate XLO as an investment opportunity.
RiverVest Venture Management LLC Buys Xilio Therapeutics IncInvestment company RiverVest Venture Management LLC (Current Portfolio) buys Xilio Therapeutics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, RiverVest Venture Management LLC. |
Xilio Therapeutics to Participate in the Guggenheim 4th Annual Oncology DayWALTHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm. D., president and chief executive officer, and Marty Huber, M.D., president of research and development and chief medical officer of Xilio Therapeutics, will participate in a virtual fireside chat during the Guggenheim 4th Annual Oncology Day on Thursday, Februa |
Are Institutions Heavily Invested In Xilio Therapeutics, Inc.'s (NASDAQ:XLO) Shares?The big shareholder groups in Xilio Therapeutics, Inc. ( NASDAQ:XLO ) have power over the company. Institutions will... |
H.C. Wainwright Reaffirms Their Buy Rating on Xilio Therapeutics (XLO)H.C. Wainwright analyst Michael King reiterated a Buy rating on Xilio Therapeutics (XLO – Research Report) today and set a price target of $36.00. The company's shares closed last Thursday at $13.62. According to TipRanks.com, King is a 4-star analyst with an average return of 13.4% and a 42.8% success rate. King covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Intellia Therapeutics, and Werewolf Therapeutics. Currently, the analyst consensus on Xilio Therapeutics is a Strong Buy with an average price target of $34.75. |
Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid TumorsWALTHAM, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that the first patient has been dosed in the company’s Phase 1/2 clinical trial evaluating XTX202 for the treatment of solid tumors. XTX202 is a modified form of IL-2 that is designed to localize activity in the tumor microenvironment (TME), with the goal of overcoming the known tolera |
XLO Price Returns
| 1-mo | -8.22% |
| 3-mo | -72.50% |
| 6-mo | -79.55% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -79.75% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...